Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NNNN with free AI briefings, catalyst countdowns, and dilution alerts.

NNNN · Anbio Biotechnology

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.9M Cash on Hand
21.2mo Cash Runway
Follow NNNN by email Get an email when NNNN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NNNN, unsubscribe in one click. Privacy

💰 Cash Runway & Dilution Risk

NNNN holds $11.9M in cash and short-term investments and burns about $1.7M/quarter from operations, an estimated runway of 21.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NNNN files for a raise →

Get the full NNNN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NNNN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.